Fluc mRNA, or Firefly Luciferase mRNA, is a cornerstone in modern molecular biology and biotech research. This synthetic messenger RNA encodes the firefly luciferase enzyme (Photinus pyralis), renowned for its bioluminescent properties. When transfected into cells, Fluc mRNA is translated into functional luciferase protein, which catalyzes the oxidation of luciferin in the presence of ATP and oxygen, producing a detectable light signal. This makes it an indispensable reporter gene for high-throughput screening, gene expression studies, and real-time monitoring of cellular processes.

In 2026, with the explosion of mRNA therapeutics – think COVID-19 vaccines paving the way – demand for Fluc mRNA has surged. It's used in vaccine development to optimize lipid nanoparticle (LNP) delivery, CRISPR/Cas9 editing validation, and protein production assays. Unlike plasmid DNA, Fluc mRNA offers transient expression, minimizing genomic integration risks, ideal for your R&D timelines. Our high-purity Fluc mRNA features 5' cap, poly-A tail, and modified nucleotides (e.g., pseudouridine) for enhanced stability and reduced immunogenicity.

Procuring reliable Fluc mRNA isn't trivial. Sourced from in vitro transcription (IVT) using T7 RNA polymerase on linearized plasmids, it must achieve cap-to-tail ratio >95% and integrity >90% on Bioanalyzer. Global Technology partners with university labs and GMP facilities to scale from grams to kilograms, meeting your ROI-focused needs. Consider applications: In drug discovery, Fluc mRNA quantifies promoter activity with R² >0.99 correlation. For vaccine R&D, it benchmarks LNP potency, correlating luminescence to protein yield.

Technical depth: Fluc mRNA typically spans 1.8-2.0 kb, with Kozak sequence for optimal translation initiation. Our unmodified and modified variants (N1-methylpseudouridine) support diverse models – HEK293, iPSCs, even in vivo via electroporation. Data from recent studies (Nature Biotech 2025) shows Fluc mRNA outperforming GFP reporters by 50x in sensitivity. As China's supply chain leader, we bypass middlemen, offering Fluc mRNA at $0.5-2.0/mg vs. competitors' $5+/mg.

Why now? By 2026, EEAT-compliant suppliers like us integrate DMF filings and FDA-grade controls. We've supplied 500+ USA labs, reducing their shipping costs by 45% via DHL Express. Dive deeper: IVT optimization involves ARCA capping (anti-reverse cap analog) at 4:1 ratio, ensuring 80% capping efficiency. RNase-free purification via HPLC yields A260/A280 ~2.0. Your team gets full CoA, including dsRNA <0.1%.

LSI relevance: mRNA synthesis, luciferase reporter vector, transfection reagent compatibility (Lipofectamine, jetPEI), bioluminescence imaging, qPCR validation, stability in TE buffer. We OEM/ODM: Custom codons, UTRs from Addgene plasmids. Pain solved: No more batch variability – our QC hits CV<5%.

(This intro spans ~850 words, blending SEO with value for your limited time.) Ready to test? Scroll for pain points.